In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma

YanXin Yu1, Shan Xu1*, Hong You1, YinJie Zhang1, Bo Yang1, XiaoYang Sun1, LingLin Yang1, Yue Chen2, ShaoZhi Fu1, and JingBo Wu1

1Department of Oncology and 2Department of Nuclear Medicine, the Affiliated Hospital of Southwest Medical University, Luzhou, China

Abstract
In this study, our purpose was to explore the synergistic anti-tumor effect and mechanism of paclitaxel nanoparticles (PTX-NPs) combined with radiotherapy (RT) on human cervical carcinoma (HeLa). PTX-NPs were prepared by a solid dispersion method using methoxy poly(ethylene glycol)-poly(e-caprolactone) (MPEG–PCL), which combined with RT exerted a potent and high efficient effect against cervical cancer. In vivo antitumor activity of PTX-NPs combined with RT, was estimated using nude mice carrying HeLa cell xenograft tumor. The results were evaluated using microfluorine-18-deoxyglucose PET/computed tomography (18F-FDG PET/CT) and immunohistochemistry. The results showed that PTX-NPs possessed a more efficient effect than PTX when combined with RT (p < 0.05). PTX-NPs in combination with RT might inhibit cell proliferation through its action on Ki-67, and decreased micro-vessel density (MVD) associated with CD31 and vascular endothelial growth factor (VEGF). These results suggested that PTX-NPs possessed a synergistic anti-tumor effect against cervical cancer when combined with RT.

Keywords
Paclitaxel, nanoparticle, radiotherapy, synergistic effect, cervical cancer

Introduction
Cervical cancer is the third most common malignant tumor in women worldwide and chemoradiotherapy is the most effective treatment in patients with locally advanced cervical cancer (Yee et al., 2013). Indeed, chemoradiotherapy improves local tumor control and the survival rate when compared to either continuous treatment or sole administration of chemotherapy or radiotherapy (RT) (Eifel, 2006; Seiwert et al., 2007). However, the synergistic use of both chemotherapy and RT has significantly higher systemic toxicity compared to either treatment alone or sequential use, due to the accumulative effect that the traditional chemotherapeutics fails to penetrate tumor interstitium in an effective concentration and increases the toxicity toward healthy tissues (Garrastazu Pereira et al., 2015; Wang et al., 2016), while the RT for cervical cancer can aggravate the side-effect causing the radiation damage to adjacent healthy tissues inevitably (Hafiz et al., 2015), such as hematological, urogenital and intestinal toxicity. Therefore, in order to reduce systemic toxicity and increase anti-tumor effect, a new drug delivery system of chemotherapy drug is in demand to the treatment of tumor. A new and exciting approach is to incorporate NPs into chemoradiotherapy. Drug delivery systems based on NPs have been extensively studied, and possess unique properties, making NPs the ideal device for the delivery of chemotherapy drugs in chemoradiotherapy, thus improving its therapeutic efficacy (Werner et al., 2011; Jung et al., 2012; Gong et al., 2013).

Paclitaxel (PTX) possesses antineoplastic activity against various types of solid tumors, verified radiosensitization, ability to inhibit microtubulin formation as well as endothelial cell proliferation and migration (Terasima & Tolmach, 1963; Downing, 2000; Pasquier et al., 2004, 2005; Schwartz, 2009; Jiang et al., 2011; Werner et al., 2013; Zhang et al., 2014; Wang et al., 2016). However, PTX also possesses short circulation half-life, poor aqueous solubility, severe side effects due to its nonselective distribution in vivo and its intratumoral concentration is too low to cause mitotic arrest, all factors that often compromise its clinical efficacy (Yu et al., 2010; Weaver, 2014). In light of these obstacles, nanotechnology offers an alternative strategy to address the drug to tumor tissue using several nanoscaled drug delivery systems (Wang X et al., 2011; Huang et al., 2012; Lu et al., 2013a; Estanqueiro et al., 2015). The solubilization of PTX is more effective in vitro and in vivo than Taxol® in many solid tumors (Passarella et al., 2010; Xin et al., 2010; Guo et al., 2013).
2011; Yang et al., 2011; Jung et al., 2012; Lv et al., 2012; Yoshizawa et al., 2012; Zhang et al., 2012, 2014; Lu et al., 2013b; Wu et al., 2014; You et al., 2016). In addition, with the development of nanotechnology, methoxy(poly(ethylene glycol))–poly(ε-caprolactone) (MPEG–PCL) polymeric micelle appears a promising drug carrier, since it is biodegradable, effective, and possesses sustained drug release properties (Wang C et al., 2011; Ding et al., 2012; Gong et al., 2013; Wu et al., 2014; You et al., 2016). Its hydrophobic surface (PCL chains) forms a core for attaching hydrophobic drugs, while the hydrophilic one (PEG chains) forms a shell to act as a stabilizing interface (Gong et al., 2010). Such core–shell structure with the drug in the core effectively protected, ensures human body a low toxicity and a prolonged circulation in the blood due to its high water-solubility (Kataoka et al., 2001). In addition, the passive accumulation of the micelles in a solid tumor is achieved by the so-called enhanced permeation and retention (EPR) (Matsumura & Maeda, 1986; Xie et al., 2007). Therefore, hydrophobic drugs can be encapsulated into the MPEG–PCL micelles and can form a stable water-based formulation for potential clinical applications.

However, no reports are available on the therapeutic effects of MPEG–PCL/PTX polymeric micelles combined with RT against cervical cancer. Therefore, the purpose of this study was to improve the efficacy of chemoradiation therapy by developing Cremophor® EL-free NPs of MPEG–PCL loaded with PTX. The PTX nanoparticles (PTX-NPs) were characterized in terms of size and surface morphology. In vitro drug release was evaluated by dialysis method. Finally, in vivo tumor growth inhibition was analyzed in BABL/c tumor bearing mice.

Materials and methods
Materials, cells and animals
ε-Caprolactone (ε-CL) (Alfa Aesar, Ward Hill, MA), poly(ethylene glycol) methyl ether (MPEG, Mn = 2000, Aldrich, St. Louis, MO), stannous octoate (Sn(Oct)2) and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (methyl thiazolytetrazolium, MTT) were purchased from Sigma-Aldrich, St. Louis, MO. Paclitaxel with 99.8% purity was purchased from Chengdu Man Site Biotechnology Co. Ltd. (Chengdu, China). PTX 5 ml: 30 mg injectable solution (Taiji Group Co., Ltd., Chengdu, China) was supplied by Southwest Medical University. Dimethyl sulfoxide (DMSO), methyl alcohol and acetonitrile (HPLC grade) were supplied by Kelong Co. Ltd. (Chengdu, China). Ki-67, CD31 and VEGF polyclonal antibodies were purchased from Bioworld Technology Co. Ltd. (Nanjing, China).

Human cervical carcinoma cells (HeLa) were provided by the Experimental Medicine Center, at the Affiliated Hospital of Southwest Medical University (Luzhou, China). HeLa cells were grown in 25 cm² glass culture flasks dissolved in 5 ml DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) and 100 IU/ml of penicillin G sodium and 100 μg/ml of streptomycin sulfate, stored in an incubator at 37 °C with 5% CO2/95% air humidified atmosphere, subcultured three times per week and used for the experiments when in exponential growth phase.

Female athymic BALB/C nude mice weighing 14–18 g (3–4 weeks) were purchased from Chongqing Tengxin Biotechnology Co. Ltd. (Chongqing, China). Mice were housed at a controlled temperature of 20–22 °C, with a 50–60% relative humidity, fed with a standard laboratory chow and tap water ad libitum. All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal experiments were approved by the Institutional Animal Care and Treatment Committee of Southwest Medical University (Luzhou, China).

Radiation was delivered at room temperature using a linear accelerator source (Medical Electronic Linear Accelerator, DRECISE-NET, Elekta, Atlanta, GA). The dose rate depended on the distance from the source. Radiation was delivered at 266.82 cGy/min for 1 min 52 s to produce a dose of 5 Gy.

Preparation of PTX-NPs
Methoxy poly(ethylene glycol)–poly(ε-caprolactone) (MEP, Mw = 4 kDa) used in this study was synthesized by ring-opening polymerization of ε-CL on MPEG using Sn(Oct)2 as catalyst, according to a previous report (Wei et al., 2009). The PTX-NPs of free PTX at the dosage of 6%, 8% or 10% (w/w) were prepared by a solid dispersion method using MPEG–PCL according to a previous report (Wang C et al., 2011).

Drug-loading (DL) and encapsulation efficiency (EE) of PTX-NPs
The drug loading and EE were determined in triplicate by a high performance liquid chromatography instrument (HPLC, Agilent 1260, Agilent Technologies, Santa Clara, CA), using a reverse phase C18 column (4.6 × 150 mm, 3.5 μm particle size). HPLC was calibrated using standard solutions of 5–100 μg/ml PTX dissolved in acetonitrile (correlation coefficient R²=0.9998). The quantification limit was 0.6 ng/ml. The coefficients of variation (CV) were all within 4.3%. The column temperature was maintained at 25 °C. Sample solution was injected at a volume of 50 μl. PTX-NPs were first dissolved in acetonitrile to destroy their package status, filtered through a 220 nm filter to obtain a sterile solution, and then the solution was measured at 227 nm. Methyl alcohol/ acetonitrile/water (38.1/23.8/38.1, v/v/v) was used in its mobile phase with a flow rate of 1.0 ml/min. Drug-loading and EE were calculated using the following equations, as previously described (Wu et al., 2014):

\[
DL\% = \frac{\text{Drug}}{\text{Polymer} + \text{Drug}} \times 100\%
\]

\[
EE\% = \frac{\text{Actual drug loading}}{\text{Theoretical drug loading}} \times 100\%
\]

Physicochemical characterization and stability study of PTX-NPs
The average particle size and size polydispersity of prepared PTX-NPs in distilled water were measured by dynamic light scattering (DLS, NanoBrook 90Plus Zeta, Brookhaven, USA)
at 25°C. PTX-NPs (DL = 8%) were chosen according to results obtained and its detailed characterization was performed. The surface morphology of the PTX-NPs was investigated by transmission electron microscope (TEM, Tecnai G2 F20, Hillsboro, OR). PTX-NPs were diluted in distilled water and placed on a copper grid covered with nitrocellulose. PTX-NPs were negatively stained with phosphotungstic acid and dried at room temperature. Moreover, the formulation stability of the PTX-NPs at a concentration of 0.2 mg/ml in PBS and 10% FBS-containing PBS, kept at 4°C or 25°C, was evaluated by DLS after ultrasonic processing. Size changes were measured at pre-determined time points and the measurement was terminated when the change of size reached a significant difference. Formulations were judged stable if no changes in particle size and no visual destabilization were observed, such as creaming, phase separation, or presence of compact aggregates. All results represent the mean of three test runs and all data were expressed as mean ± standard deviation (SD).

**In vitro drug release**

To measure PTX release profile from PTX-NPs, 1.0 ml PTX-NPs solution (theoretical drug loading rate was 8%) and 1.0 ml free PTX solution in dehydrated alcohol at a concentration of 0.5 mg/ml were placed in dialysis bags (molecular mass cutoff was 8.0–14 kDa). The dialysis bags were incubated in 40 ml PBS (pH = 7.4) containing Tween 80 (0.5%, w/v) at 37°C with gentle shaking (100 rpm). At predetermined time points, 2 ml aliquots of the dialysis medium were collected, and the same volume of fresh pre-warmed medium was added. The collected medium was centrifuged at 12,000 rpm for 15 min at 4°C. The supernatant was collected and stored at −20°C for further analysis. All samples were measured using HPLC as described in section Drug-loading (DL) and encapsulation efficiency (EE) of PTX-NPs, and data represent the mean of a triplicate and expressed as mean ± SD.

**In vivo anti-tumor efficacy of RT combined with PTX-NPs**

Athymic BALB/C nude mice were subcutaneously treated in the right flank with 0.1 ml of Hela cell suspension containing \(1 \times 10^6\) cells. Administration of the compounds listed below started at day 15 after inoculation when the tumor size reached approximately 200 mm\(^3\). On that day, mice were euthanized 24 h after treatment; the remaining mice in each group were used to investigate the tumor regrowth delay (TGD) and animal survival. Animals’ tumor volumes and body weight were measured every three days using the formula as previously described (You et al., 2016): \(V = 0.5 \times a \times b^2\), where \(V\) is the tumor volume, \(a\) is the length of the major axis and \(b\) is the length of the minor axis.

**Micro \(^{18}\)F-FDG PET/CT imaging**

To investigate the tumor tissues’ metabolism early response in Control, PTX + RT and PTX-NPs + RT group, we performed micro PET/CT scans and image analysis using an Inveon micro PET/CT (Siemens, Munich, Germany) animal scanner at one day after the end of treatment. Mice were fasted 12 h, intraperitoneal anesthetized with 1% pentobarbital 5 ml/kg and 100–200 μCi FDG was intravenously injected in the tail prior to scan. Mice were positioned in the center PET ring field of view and PET/CT images were acquired 1 h after \(^{18}\)F-FDG administration. The parameters used were as follows: 80 kV, 500 μA, 1.5 mm slice thickness and 10 min per bed position.

According to a previous report (You et al., 2016), the image plane with the largest tumor appearance on the PET/CT fusion image was selected for data collection. An irregular region of interest (ROI) covering the entire tumor was manually drawn. ROIs were also drawn on the contralateral paraspinal muscles. Tracer uptake value in tumor and muscle tissue was determined in the attenuation-corrected transaxial tomographic slices by calculating the standard uptake value (SUV) and was measured by means of ROI. \(^{18}\)F-FDG maximum SUV of each lesion was obtained from the selected ROI and compared to the SUVs of the contralateral paraspinal to calculate the tumor/muscle (T/M) ratio.

**Ki-67, CD31 and VEGF immunohistochemistry**

Tumor tissues were harvested and fixed with 4% formaldehyde. Next paraffin-embedded 4-μm thick sections were cut for hematoxylin and eosin (H&E) histological staining and immunohistochemistry. Briefly, tissues were incubated with anti-human Ki-67, CD31 and VEGF, primary antibodies, and a biotinylated goat anti-mouse antibody was used as secondary antibody. Then the slides were washed with PBS and incubated with dianinobenzidine (DAB) chromogen for 3–5 min to yield a dark brown color. The sections were counter-stained with hematoxylin for microscopic observation (Leica TE2000-S Microscope, Tokyo, Japan).

Ki-67 and VEGF expressions were calculated in five randomly selected areas in each tumor sample as the number of positive cells/total were counted at 400× magnification. Cells with moderate and strong brownish cytoplasmic staining were considered as positive, whereas cells with unstained or weakly stained cytoplasm were considered as negative.

Micro-vessel density (MVD) was determined as previously reported (Makitie et al., 1999) and expressed as the mean value of the area of microvessels in five CD31-highly positive hotspots.

**Statistical analysis**

The statistical analysis was carried out using SPSS 13.0 software (Chicago, IL) and performed by Student’s \(t\)-test for
two groups or one-way ANOVA for multiple groups. Means were considered different when $p < 0.05$.

**Results**

**PTX content and PTX-NPs physicochemical characterization**

In this study, the theoretical DL into PTX-NPs was set at 6%, 8% and 10% (wt%). According to DL%, EE% and particle size (Table 1), 8% (7.96 ± 0.06) showed a better actual drug loading than 6% (4.33 ± 0.12) and 10% (8.79 ± 0.17). Therefore, we considered PTX-NPs 8% theoretical DL in our further experiments. The size and dispersity of prepared PTX-NPs were confirmed by TEM morphology (Figure 1A,B), showing well-dispersed nanoparticles into an aqueous solution. The formulation stability of PTX-NPs as shown in Figure 1(C), stayed stable for 48 h in each group without using any stabilizer.

**In vitro drug release**

Free PTX exhibited a rapid release behavior, and more than 97% of the drug was released within four days. However, only 63.48% PTX was slowly released from the PTX-NPs in 14 days, with no burst effect, as compared to free PTX (Figure 2).

**In vivo tumor growth inhibition**

To evaluate the efficacy of PTX-NPs combined with RT on HeLa xenograft in mice, tumor volume and median survival time were measured and plotted after each treatment. After 22 days, the tumor volume of PTX-NPs + RT group (623.5 mm$^3$) was significantly smaller than PTX + RT group (1121.4 mm$^3$, $p < 0.01$), RT group (1176.9 mm$^3$, $p < 0.01$), PTX-NPs group (2074.1 mm$^3$, $p < 0.01$), PTX group (2197.2 mm$^3$, $p < 0.01$) and NS group (2347.2 mm$^3$, $p < 0.01$) (Figure 3A). These results demonstrated that PTX-NPs + RT possessed a more powerful ability on reducing the cervical tumor volume.

Mice median survival time (Figure 3B) in the PTX-NPs + RT group was significantly longer (87 days) compared to the PTX + RT group (61 days, $p < 0.01$), RT group (64 days, $p < 0.01$), PTX-NPs group (31 days, $p < 0.01$), PTX group (34 days, $p < 0.01$) and NS group (25 days, $p < 0.01$), suggesting that PTX-NPs was more effective, compared to PTX, when combined with RT. Body weight measurements showed no significant differences between the groups throughout the entire study. A slight increase in body mass was observed as a result of natural animal growth (data not shown).

**Micro $^{18}$F-FDG PET imaging**

The T/M values of each group were 2.635 ± 0.074 (NS), 2.032 ± 0.214 (PTX + RT) and 1.182 ± 0.043 (PTX-NPs + RT). Both PTX + RT and PTX-NPs + RT groups showed a decrease in T/M value compared to the NS group, although the T/M value in PTX-NPs + RT group was the lowest ($p < 0.05$), suggesting a more powerful effect of PTX-NPs, when combined with RT, than PTX + RT (Figure 4).

| Samples | Theoretical DL (%) | DL (%) | EE (%) | Size (nm) | PDI |
|---------|--------------------|--------|--------|-----------|-----|
| 1       | 6%                 | 4.33 ± 0.12 | 92.76 ± 0.29 | 43.34 ± 0.27 | 0.21 ± 0.04 |
| 2       | 8%                 | 7.96 ± 0.06 | 99.78 ± 0.34 | 45.71 ± 0.32 | 0.19 ± 0.02 |
| 3       | 10%                | 9.79 ± 0.17 | 97.90 ± 0.17 | 49.36 ± 0.40 | 0.20 ± 0.05 |

Figure 1. Physicochemical characterization and stability study of PTX-NPs. (A) PTX-NPs particle size distribution; (B) TEM image of PTX-NPs and (C) the formulation stability of the PTX-NPs. Data are shown as means ± SD ($n = 3$).
Immunohistochemistry

A small number of Ki-67 positive cells was observed in the PTX-NPs + RT group (21.7 ± 7.5%) compared to PTX + RT group (40.6 ± 4.4%, p < 0.05), RT group (57.2 ± 5.0%, p < 0.05), PTX-NPs group (73.2 ± 5.8%, p < 0.05), PTX group (79.6 ± 6.2%, p < 0.05) or NS group (87.2 ± 4.0%, p < 0.05) (Figure 5).

Fewer immunoreactive microvessels were observed in the tumor tissue sections of PTX-NPs + RT treated mice (Figure 6). The area of microvessel percentage of the MVD area in the PTX-NPs + RT group (2.1 ± 0.3%) was dramatically lower compared to the PTX + RT group (3.8 ± 0.4%, p < 0.05), RT group (4.2 ± 0.8%, p < 0.05), PTX-NPs group (8.7 ± 0.7%, p < 0.05), PTX group (9.0 ± 0.4%, p < 0.05) or NS group (9.8 ± 0.7%, p < 0.05).

The expression of VEGF protein in the PTX-NPs + RT group was 30.7 ± 4.0%, that was actually significantly lower than that of the PTX + RT group (85.6 ± 3.5%, p < 0.01), RT group (89.7 ± 3.5%, p < 0.01), PTX-NPs group (75.7 ± 3.2%, p < 0.01), PTX group (77.4 ± 5.1%, p < 0.01) or NS group (80.0 ± 5.0%, p < 0.01, Figure 7).

Discussion

In the present work, the method we used to obtain PTX-NPs allowed us to obtain nanoparticles with a specific stability, EE and drug loading according to previous studies (Wang C et al., 2011). The most important aspect of these results was that the obtained size prevents nanoparticles renal filtration during
circulation in the human body, thus increasing the blood circulation time and facilitating an effective and powerful targeting of the tumor through the EPR effect (Xu et al., 2015). In addition, although it was kept stable for a much shorter time (48 h) without any stabilizing agent compared to the study using soybean LEC for stabilization (Kumar et al., 2014), the lyophilized nanoparticles could be homogeneously and stably dissolved, as previously reported (Wu et al., 2014).

Figure 5. Ki-67 immunohistochemical staining in tumors. (A) Ki-67 immunohistochemical images of tumor tissue from mice in various groups. (B) Ki-67 quantitative analysis in xenografts from mice in various groups. *p<0.05 and **p<0.01. Original magnification, ×400.

Figure 6. CD31 immunohistochemical staining of tumors. (A) CD31 immunohistochemical images of tumor tissue from mice in various groups. (B) CD31 quantitative analysis in xenografts from mice in various groups. *p<0.05 and **p<0.01. Original magnification, ×400.

Figure 7. VEGF immunohistochemical staining in tumors. (A) VEGF immunohistochemical images of tumor tissue from mice in various groups. (B) VEGF quantitative analysis in xenografts from mice in various groups. *p<0.05 and **p<0.01. Original magnification, ×400.
ensuring the best solubility into the blood and on the same time, and they were more suitable for storage and large-scale production.

The sustained and slow drug release exhibited by PTX-NPs could be due to the stable structure of polymeric micelles, since it might be attributed to the diffusion of the drug localized in the PCL core of the nanoparticles, suggesting that our PTX-NPs had an excellent drug loading and EE. The rapid drug release by free PTX indicated that the dialysis membrane had no effect on retarding the release of the drug from nanoparticles, also underlining that PTX-NPs drug release mechanisms are diffusion, erosion and swelling of the polymer matrix, as well as its degradation (Zhang & Feng, 2006). The burst release of PTX in other studies (Wu et al., 2014) may be due to the dissolution and diffusion of the drug that was poorly entrapped in the polymer matrix. Some studies have reported that the NPs cumulative drug release within one month is usually 30–40% or less, which may be too slow to meet the therapeutic needs (Mu & Feng, 2002; Zhang & Feng, 2006). Thus, our PTX-NPs possessed the great advantage of an increased drug release rate. This can be due to the PEG content in the material, giving to the NPs a hydrophilic character, leading to a faster release of the drug. Such drug release we obtained could thus allow an increased synergistic effect between PTX and RT, which in turn could result in an improved therapeutic efficacy.

In vivo experiments, we demonstrated that at equivalent PTX doses, PTX-NPs led to a significantly longer delay on tumor growth and the survival time than PTX injection in mice treated with chemoradiation therapy. It is important to note that in this study we used a relatively low dose of PTX, suggesting that PTX-NPs paclitaxel was more effective than PTX on cervical cancer due to the EPR of NPs.

According to a previous study (Avril et al., 2011), a higher FDG uptake in tumors suggested a poor response and prognosis while a lower FDG uptake may indicate a better response to treatment. Our result showing the lowest 18F-FDG uptake by PTX-NPs + RT group suggested that PTX-NPs enhanced RT effect to a greater extent compared to PTX injection.

Furthermore, the percentage of Ki-67 positive cells in each groups exhibited an analogous difference in the tumor growth delay and mice median survival time. In addition, a similar difference was also found in the MVD area and CD31-positive vessels, suggesting that PTX-NPs combined with RT might contribute to the suppression of cell proliferation and angiogenesis

However, compared PTX + RT group to RT group, although the expression of VEGF had no statistically significant as the expression of Ki-67 or CD-31, the expression of VEGF was higher than other non-RT groups. VEGF is a protein secreted by tumor cells to promote angiogenesis through proliferation, migration, and the survival of endothelial cells acting as an antiapoptotic factor. It also involved in cervical cancer (Stepan et al., 2012; Wachsberger et al., 2012; Barbu et al., 2013; Du et al., 2014; Shi et al., 2015). Thus, VEGF elevated expression as we observed in RT alone or with PTX might contribute to the resistance to radiation in tumors (Zhou et al., 2012). On the other hand, VEGF in the PTX-NPs + RT group reached the lowest expression, compared to the other groups, suggesting that PTX-NPs play a role in decreasing VEGF against the increased level of RT, which in turn suggest that PTX released from NPs modulated the interaction between the tumor and its microenvironment due to the EPR of NPs. Furthermore, the VEGF, which is associated with MVD, influenced by RT might be instantaneous, and the decreased area of microvessel contributed to the directly destroy of RT and the EPR of PTX-NPs.

Conclusions

In this study, a NPs drug delivery system composed of PTX micelles was prepared and its in vivo anti-tumor activity was investigated in a mouse model for cervical cancer. The PTX-NPs were prepared by solid dispersion method and produced a compound with high DL, high EE, spherical morphology and monodispersity. In vitro drug release experiments showed that the PTX-NPs could release PTX in a controlled manner. The in vivo assay showed that the PTX-NPs at a low dose combined with RT can significantly inhibit tumor growth and prolong the survival time of tumor-bearing mice. PET/CT imaging on the HeLa xenograft model also verified that PTX-NPs enhanced the effect of RT compared to PTX injection. Analysis of tissue biomarkers showed that the PTX-NPs combined with RT suppressed tumor cell proliferation and inhibited angiogenesis in tumor tissue. Thus, the results indicated that PTX-NPs had an obviously efficient for cervical cancer without an accumulation antitumor efficient of PTX but a synergism of PTX combined with RT.

Acknowledgements

The authors would like to show their great thanks to Yun Ye (Department of Pharmacy, the Affiliated Hospital of Southwest Medical University) due to her great help in HPLC analysis.

Declaration of interest

The authors report no declarations of interest.

This work was financially supported by the Union Project of Luzhou City and Southwest Medical University (14JC0144, 2013LZLY-J40).

References

Avril N, Gourtsoyianni S, Reznek R. (2011). Gynecological cancers. Methods Mol Biol 727:171–89.
Barbu I, Cra˘it ¸ oiu S, Simionescu CE, et al. (2013). Cd105 microvessels density, vegf, egfr-1 and c-erbb-2 and their prognostic correlation in different subtypes of cervical adenocarcinoma. Roman J Morphol Embryol = Rev Roumain Morphol Embryol 54:519–30.
Ding D, Wang J, Zhu Z, et al. (2012). Tumor accumulation, penetration, and antitumor response of cisplatin-loaded gelatin/poly(acrylic acid) nanoparticles. ACS Appl Mater Interfaces 4:1838–46.
Downing KH. (2000). Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics 1. Annu Rev Cell Dev Biol 16:89–111.
Du K, Gong H-Y, Gong Z-M. (2014). Influence of serum vegf levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer. Asian Pac J Cancer Prev 15:8793–6.
Eifel PJ. (2006). Chemoradiotherapy in the treatment of cervical cancer. Semin Radiat Oncol 16:177–85.
Y. Yu et al.  

Drug Deliv, 2017; 24(1): 75-82

Estanqueiro M, Amaral MH, Conceicaco J, et al. (2015). Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces 126:631–48.

Garrastazu Pereira G, Lawson AJ, Buttini F, et al. (2015). Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv. [Epub ahead of print]. doi:10.3109/10717544.2015.1141047.

Gong C, Deng S, Wu Q, et al. (2013). Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 34:1413–22.

Gong C, Wang Y, Wang X, et al. (2010). Biodegradable self-assembled peg-pcl-peg micelles for hydrophobic drug delivery. Part 2: In vitro and in vivo toxicity evaluation. J Nanopart Res 13:721–31.

Guo J, Gao X, Su L, et al. (2011). Aptamer-functionalized peg-plga nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010–20.

Hafiz A, Abbasi AN, Ali N, et al. (2015). Frequency and severity of acute toxicity of pelvic radiation for gynecological cancer. J Coll Phys Surg–Pakistan: JCPSP 25:802–6.

Huang Y, Lu J, Gao X, et al. (2012). Peg-derivated embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem 23:1443–51.

Jiang X, Xin H, Sha X, et al. (2011). Pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. Int J Pharm 420:385–94.

Jung J, Park S-J, Chung HK, et al. (2012). Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84:e77–83.

Kataoka K, Harada A, Nagasaki Y. (2001). Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47:113–31.

Kumar BS, Saraswathi R, Kumar KV, et al. (2014). Development and characterization of lecithin stabilized glibencamide nanocrystals for enhanced solubility and drug delivery. Drug Deliv 21:173–84.

Lu J, Huang Y, Zhao W, et al. (2013a). Design and characterization of peg-derivative vitamin e as a nanomicellar formulation for delivery of paclitaxel. Mol Pharm 10:2880–90.

Lu J, Huang Y, Zhao W, et al. (2013b). Peg-derivated embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials 34:1591–600.

Lv PP, Ma YF, Yu R, et al. (2012). Targeted delivery of insoluble cargo (paclitaxel) by pegylated chitosan nanoparticles grafted with arg-gly-asp (rgd). Mol Pharm 9:1756–47.

Makitte T, Summanen P, Tarkkanen A, et al. (1999). Microvascular density in predicting survival of patients with chorial and ciliary body melanoma. Invest Ophthalmol Vis Sci 40:2471–80.

Matsumura Y, Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6587–92.

Mu L, Feng SS. (2002). Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (taxol). J Control Release 80:129–44.

Yee GP, de Souza P, Khachigian LM. (2013). Current and potential treatments for cervical cancer. Curr Cancer Drug Targets 13:205–20.

Pasquier E, Carré M, Pourroy B, et al. (2004). Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3:1301–10.

Pasquier E, Honore S, Pourroy B, et al. (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65:2433–40.

Passarella RJ, Spratt DE, van der Ende AE, et al. (2010). Targeted nanoparticles that deliver a sustained, specific release of paclitaxel to irradiated tumors. Cancer Res 70:4550–9.

Schwartz EL. (2009). Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594–601.

Seiwert TY, Salama JK, Vokes EE. (2007). The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol 4:86–100.

Shi C, Cao H, He W, et al. (2015). Novel drug delivery liposomes targeted with a fully human anti-vegf165 monoclonal antibody show superior antitumor efficacy in vivo. Biomed Pharmacother 73:48–57.

Stepan D, Simionesco C, Stepan A, et al. (2012). Vegf and cd105 immunoeexpression in squamous cervical carcinomas and associated precancerous lesions. Rom J Morphol Embryol 53:585–9.

Terasima T, Tolmach LJ. (1963). X-ray sensitivity and DNA synthesis in synchronous populations of hela cells. Science 140:490–2.

Wachsberger PR, Lawrence YR, Liu Y, et al. (2012). Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. Int J Radiat Oncol Biol Phys 82:483–91.

Wang C, Wang Y, Wang et al. (2011). Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm 414:251–9.

Wang X, Li J, Wang Y, et al. (2011). A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 5:6184–94.

Wang ZY, Zhang H, Yang et al. (2016). Preparation, characterization, and efficacy of thermosensitive liposomes containing paclitaxel. Drug Deliv 23:1222–31.

Weaver BA. (2014). How taxol/paclitaxel kills cancer cells. Mol Biol Cell 25:2677–81.

Wei X, Gong C, Gou M, et al. (2009). Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm 381:1–18.

Werner ME, Copp JA, Karve S, et al. (2011). Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 5:8990–8.

Werner ME, Cummings ND, Sethi M, et al. (2013). Preclinical evaluation of genexol-pm, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86:463–8.

Wu Z, Zou X, Yang L, et al. (2014). Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer. Colloids Surf B Biointerfaces 122:90–8.

Xie Z, Guan H, Chen X, et al. (2007). A novel polymer-paclitaxel conjugate based on amphiphilic triblock copolymer. J Control Release 117:210–16.

Xin H, Chen L, Gu J, et al. (2010). Enhanced anti-glioblastoma efficacy by ptx-loaded pegylated poly(c-caprolactone) nanoparticles: in vitro and in vivo evaluation. Int J Pharm 402:238–47.

Xu Z, Liu S, Kang Y, et al. (2015). Glutathione- and pH-responsive nanoporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale 7:5859–68.

Yang D, Van S, Jiang X, et al. (2011). Novel free paclitaxel-loaded nanoparticle minimizes drug resistance in a human cancer model. Biomaterials 32:8010–20.

Yoshizawa Y, Ogawara K, Fushimi A, et al. (2012). Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor su5416. Mol Pharm 9:3486–94.

You H, Fu S, Qin X, et al. (2016). A study of the synergistic effect of folate-decorated polymeric micelles incorporating hydroxycamptothecin with radiotherapy on xenografted human cervical carcinoma. Colloids Surf B Biointerfaces 140:150–60.

Yu DH, Lu Q, Xie J, et al. (2010). Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovascularature. Biomaterials 31:2278–92.

Zhang P, Hu L, Yin Q, et al. (2012). Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery; synthesis, preparation and in vivo evaluation. J Control Release 159:429–34.

Zhang P, Huang Y, Liu H, et al. (2014). A peg-fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials 35:7146–56.

Zhang S, Feng SS. (2006). Nanoparticles of poly(lactide)/vitamin e tpgs copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262–70.

Zhou J, Wang L, Xu X, et al. (2012). Antitumor activity of endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett 4:976–80.